Labiana brings its new zero milk-withdrawal antibiotic for dairy cattle to ANEMBE
- Labiana thus presents a significant breakthrough for the livestock sector, as until now there was no antibiotic with zero milk withdrawal time in dairy cattle classified in groups C and D.
- Not only does it improve animal welfare and quality of life, but it also facilitates farm management and enhances productivity.
- It is prescribed for the treatment of dermatological infections, metritis, wounds, abscesses, and septic mastitis in cattle.
Madrid, May 27, 2025 – Labiana, the pharmaceutical laboratory specializing in both animal and human health and listed on BME Growth, will present its latest additions to its product portfolio at the ANEMBE International Congress of Bovine Medicine, taking place from May 28 to 30 in Vitoria. Among the highlights is a new antibiotic with zero milk withdrawal time in dairy cattle.
Specifically, it is the only first-generation injectable cephalosporin (cephalexin) registered for use in cattle within group C antibiotics. Labiana thus offers a significant advance for the livestock sector—highly sought after by veterinarians—since until now, there were no antibiotics with zero milk withdrawal time in dairy cattle classified in groups C or D (“caution” and “prudence”) under the prudent-use categories recommended by the European Medicines Agency (EMA) to prevent cross-bacterial resistance.
Cephalexin does not cross the mammary barrier nor is it excreted in milk, which allows milk production to continue uninterrupted during treatment. This not only supports animal welfare and quality of life, but also simplifies farm operations and boosts productivity.
This antibiotic is also highly versatile and is prescribed to treat dermatological infections, metritis, wounds, abscesses, and septic mastitis in cattle.
Additionally, Labiana will present other flagship solutions for cattle welfare at the congress, such as its long-acting formulations, which provide prolonged therapeutic effects with a single intramuscular injection, resulting in more precise recovery outcomes.
One of these long-acting veterinary antibiotics being showcased at ANEMBE is designed for treating infections in both sheep and cattle, providing extended action and sustained antibacterial activity. It falls under Category D—first-line treatments considered to pose a lower risk of cross-resistance in humans.
Cattle, along with pigs and sheep/goats, are among the main livestock species in Spain and represent one of the most important agri-food productions across the European Union. That is why Labiana has dedicated substantial efforts to this sector since its beginnings. With more than 60 years of history tied to livestock and one of the leading injectable production facilities in Spain located in Terrassa, Labiana is a national benchmark in animal health.
Currently, the company’s cattle-focused catalog includes a broad range of anti-infectives, anti-inflammatories, antiparasitics, hormonal treatments, metabolic regulators, injectable and oral vitamins, nutritional supplements, and veterinary instruments.
According to Antonio José Ortiz, Commercial Director of Labiana Life, “ANEMBE is the leading event in the field of bovine health. As every year, we will be presenting important additions to our product portfolio, such as this new zero-withdrawal-time antibiotic for dairy cattle—an innovation that improves animal welfare and directly boosts the productivity of a sector that will find us this week at booths 37 and 38.”
About Labiana
Labiana Health is an independent, integrated international leader in animal and human health, with a diversified portfolio of products and businesses and a broad client base of top-tier companies with long-lasting relationships built on trust. It has subsidiaries in Spain, Serbia, Turkey, and Mexico, with production centers distributed between Spain and Serbia. Labiana’s products are present in over 150 markets, with product registrations in more than 90 countries. The group has two differentiated and complementary business lines: contract manufacturing in both veterinary and human health, which provides stability and income visibility, and the development, manufacturing, and commercialization of its own products in both animal and human health, driving growth. The company debuted on BME Growth in June 2022, becoming the first veterinary company to list on Spain’s BME Growth Market.
FORWARD-LOOKING STATEMENTS
This communication may contain information and forward-looking statements or declarations regarding LABIANA. It may also include financial projections and/or estimates with their underlying assumptions, statements concerning plans, objectives, and expectations regarding future operations, investments, synergies, products, and services, as well as statements about future results. Forward-looking statements are not historical facts and are generally identified by the use of terms such as “expects,” “anticipates,” “believes,” “intends,” “estimates,” and similar expressions.
While LABIANA believes that the expectations reflected in such statements are reasonable, investors and shareholders of LABIANA are cautioned that forward-looking information and statements are subject to risks and uncertainties, many of which are difficult to predict and are generally beyond the control of LABIANA. These factors could cause actual results and developments to differ significantly from those expressed, implied, or projected in the forward-looking information and statements.
Such risks and uncertainties include those identified in documents submitted by LABIANA to BME Growth, which are publicly accessible. It is recommended not to make decisions based on forward-looking statements, as they refer solely to the date on which they were made, do not constitute a guarantee of future results, and have not been audited by LABIANA’s auditors.
All forward-looking statements or declarations, whether oral or written, made by LABIANA or any of its board members, executives, employees, or representatives are expressly subject to these warnings. The forward-looking statements or declarations included in this document are based on the information available to LABIANA as of the date of this communication.
Leave a Comment